JP2000281586A - Bone-strengthening agent - Google Patents
Bone-strengthening agentInfo
- Publication number
- JP2000281586A JP2000281586A JP11090561A JP9056199A JP2000281586A JP 2000281586 A JP2000281586 A JP 2000281586A JP 11090561 A JP11090561 A JP 11090561A JP 9056199 A JP9056199 A JP 9056199A JP 2000281586 A JP2000281586 A JP 2000281586A
- Authority
- JP
- Japan
- Prior art keywords
- iron
- lactoferrin
- bone
- solution
- strengthening agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000005728 strengthening Methods 0.000 title claims abstract description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 100
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 79
- 229910052742 iron Inorganic materials 0.000 claims abstract description 50
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 35
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 25
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 25
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims abstract description 10
- 210000000988 bone and bone Anatomy 0.000 claims description 23
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 208000020084 Bone disease Diseases 0.000 abstract description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 7
- 239000011575 calcium Substances 0.000 abstract description 7
- 229910052791 calcium Inorganic materials 0.000 abstract description 7
- 235000001465 calcium Nutrition 0.000 abstract description 7
- 208000001132 Osteoporosis Diseases 0.000 abstract description 6
- 230000004097 bone metabolism Effects 0.000 abstract description 3
- 235000003891 ferrous sulphate Nutrition 0.000 abstract description 3
- 239000011790 ferrous sulphate Substances 0.000 abstract description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 abstract description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 abstract description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 2
- 229930003316 Vitamin D Natural products 0.000 abstract description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 2
- 229930003448 Vitamin K Natural products 0.000 abstract description 2
- 229960005069 calcium Drugs 0.000 abstract description 2
- 239000004222 ferrous gluconate Substances 0.000 abstract description 2
- 235000013924 ferrous gluconate Nutrition 0.000 abstract description 2
- 229960001645 ferrous gluconate Drugs 0.000 abstract description 2
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 abstract description 2
- 239000011777 magnesium Substances 0.000 abstract description 2
- 229910052749 magnesium Inorganic materials 0.000 abstract description 2
- 235000001055 magnesium Nutrition 0.000 abstract description 2
- 229940091250 magnesium supplement Drugs 0.000 abstract description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 abstract description 2
- 235000019166 vitamin D Nutrition 0.000 abstract description 2
- 239000011710 vitamin D Substances 0.000 abstract description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract description 2
- 235000019168 vitamin K Nutrition 0.000 abstract description 2
- 239000011712 vitamin K Substances 0.000 abstract description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 abstract description 2
- 229940046008 vitamin d Drugs 0.000 abstract description 2
- 229940046010 vitamin k Drugs 0.000 abstract description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 235000013305 food Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000009616 inductively coupled plasma Methods 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- -1 for example Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000014214 soft drink Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 229940072440 bovine lactoferrin Drugs 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940044631 ferric chloride hexahydrate Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000013611 frozen food Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000011962 puddings Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 1
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- GLMQHZPGHAPYIO-UHFFFAOYSA-L azanium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [NH4+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O GLMQHZPGHAPYIO-UHFFFAOYSA-L 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000004993 emission spectroscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940032296 ferric chloride Drugs 0.000 description 1
- 235000007144 ferric diphosphate Nutrition 0.000 description 1
- 239000011706 ferric diphosphate Substances 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- ATEAWHILRRXHPW-UHFFFAOYSA-J iron(2+);phosphonato phosphate Chemical compound [Fe+2].[Fe+2].[O-]P([O-])(=O)OP([O-])([O-])=O ATEAWHILRRXHPW-UHFFFAOYSA-J 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、鉄−ラクトフェリ
ンを有効成分とする骨強化剤に関する。本発明の骨強化
剤は、骨粗鬆症等の各種骨疾患の予防及び治療に有効で
ある。The present invention relates to a bone strengthening agent containing iron-lactoferrin as an active ingredient. The bone enhancer of the present invention is effective for the prevention and treatment of various bone diseases such as osteoporosis.
【０００２】[0002]
【従来の技術】日本人の鉄分摂取量は、昭和50年以降、
栄養所要量の充足率 100％前後を横ばいで推移している
現状にあり、食事上、鉄分は気をつけて摂取しなければ
ならない栄養素といえる。特に、貧血傾向の人や妊産婦
は鉄が不足しがちとなるため、十分な鉄の摂取が望まれ
る。[Prior Art] The iron intake of Japanese people has been increasing since 1975
Nutrition requirements are currently leveling off at around 100%, and iron can be said to be a nutrient that must be taken with care when eating. Particularly, anemia-prone people and pregnant women tend to lack iron, so it is desirable to take sufficient iron.
【０００３】また、近年、骨粗鬆症、骨折及び腰痛等の
各種骨疾患を患う人が急速に増加しており、その予防や
治療法の確立が急がれている。こうした社会情勢を背景
として、骨及びカルシウム代謝に関する研究は飛躍的に
発展しているが、未だ研究の余地を残している。骨粗鬆
症等の骨疾患はカルシウムの摂取不足、カルシウム吸収
能力の低下及び閉経後のホルモン・アンバランス等が原
因であるとされている。このような骨疾患を予防するた
めには、小児期、青年期に出来るだけ多くの骨量を獲得
し、最大骨量を増加させることが極めて重要であるとさ
れている。骨量を増加させるためには、カルシウムをよ
り多く摂取することが重要である。[0003] In recent years, the number of people suffering from various bone diseases such as osteoporosis, bone fracture and back pain has been rapidly increasing, and prevention and treatment methods thereof are urgently required. Against the background of these social situations, research on bone and calcium metabolism has been dramatically developed, but there is still room for research. It is said that bone diseases such as osteoporosis are caused by insufficient calcium intake, decreased calcium absorption ability, and hormonal imbalance after menopause. In order to prevent such bone diseases, it is extremely important to obtain as much bone mass as possible during childhood and adolescence and to increase the maximum bone mass. In order to increase bone mass, it is important to consume more calcium.
【０００４】また、骨は、カルシウムのみならず、コラ
ーゲン等のタンパク質からも構成されている。鉄は、プ
ロコラーゲンプロリンヒドロキシラーゼとプロコラーゲ
ンリジンヒドロキシラーゼの補酵素としてコラーゲンの
前駆体のプロリン及びリジンの水酸化に必須であり、骨
の基質であるコラーゲンの成熟化にも重要な役割を果た
していると考えられる。[0004] Bone is composed of not only calcium but also proteins such as collagen. Iron is essential as a coenzyme for procollagen proline hydroxylase and procollagen lysine hydroxylase in the hydroxylation of proline and lysine, a precursor of collagen, and plays an important role in the maturation of collagen, a bone matrix. It is thought that there is.
【０００５】しかしながら、鉄−ラクトフェリンが骨強
化作用を有することは知られていなかった。However, it has not been known that iron-lactoferrin has a bone strengthening effect.
【０００６】[0006]
【発明が解決しようとする課題】したがって、本発明
は、鉄−ラクトフェリンを有効成分とする新規な骨強化
剤を提供することを課題とする。Accordingly, an object of the present invention is to provide a novel bone strengthening agent containing iron-lactoferrin as an active ingredient.
【０００７】[0007]
【課題を解決するための手段】本発明者らは、上記の問
題点に鑑み、骨粗鬆症等の各種骨疾患の予防及び治療に
有効な骨強化剤を提供することを目的として、検討を重
ねた結果、鉄−ラクトフェリンが骨強化作用を有するこ
とを見出し、本発明を完成するに至った。Means for Solving the Problems In view of the above-mentioned problems, the present inventors have repeatedly studied for the purpose of providing a bone strengthening agent effective for prevention and treatment of various bone diseases such as osteoporosis. As a result, they found that iron-lactoferrin has a bone strengthening effect, and completed the present invention.
【０００８】ラクトフェリン類は、通常１分子当たり２
原子の鉄をキレート結合する能力を有しており、これは
ラクトフェリン類1g当たり鉄 1.4mgを結合することに相
当する。それに対して、本発明で用いる鉄−ラクトフェ
リンは、ラクトフェリン類１分子当たり少なくとも３原
子の鉄を安定に保持できるようにしたものである。この
ような鉄−ラクトフェリンとすることにより、多量の鉄
をラクトフェリン類に結合させることができる。このよ
うな鉄−ラクトフェリンは従来より知られており、例え
ば、ラクトフェリンを水に溶解し、これに鉄化合物を添
加してラクトフェリンと鉄とを反応させて溶液中の鉄を
非遊離状態にして得られる鉄−ラクトフェリン〔特開平
4-141067号公報〕、ラクトフェリン溶液に鉄塩を添加
し、アルカリを加えて溶液のpHを上げて得られる鉄を安
定に保持するラクトフェリン粉末〔特開平7- 17825号公
報〕、ラクトフェリンのアミノ基に重炭酸イオンを介し
て鉄が結合した耐熱性鉄−ラクトフェリン結合体〔特開
平6-239900号公報〕、あるいは、炭酸及び／又は重炭酸
とラクトフェリンとを含む溶液に鉄を含有する溶液を混
合して得られる鉄−ラクトフェリン複合体〔特開平7-30
4798号公報〕等を例示することができる。[0008] Lactoferrin is usually 2 per molecule.
It has the ability to chelate atomic iron, which corresponds to 1.4 mg iron / g lactoferrins. On the other hand, the iron-lactoferrin used in the present invention can stably hold at least 3 atoms of iron per lactoferrin molecule. By using such iron-lactoferrin, a large amount of iron can be bound to lactoferrins. Such iron-lactoferrin has been known in the art.For example, lactoferrin is dissolved in water, an iron compound is added thereto, and lactoferrin and iron are reacted to make iron in the solution non-free. Iron-lactoferrin [JP
4-141067 publication), adding an iron salt to a lactoferrin solution, adding an alkali to raise the pH of the solution to thereby stably retain iron obtained by raising the pH of the solution (Japanese Patent Application Laid-Open No. 7-17825), and amino groups of lactoferrin Heat-resistant iron-lactoferrin conjugate in which iron is bound via bicarbonate ions (Japanese Patent Application Laid-Open No. 6-239900), or a solution containing carbonic acid and / or bicarbonate and lactoferrin mixed with a solution containing iron Iron-lactoferrin complex (JP-A-7-30
No. 4798] and the like.
【０００９】本発明では、鉄−ラクトフェリンとして、
前記のいずれのものでも用いることができる。すなわ
ち、本発明でいう鉄−ラクトフェリンは、鉄とラクトフ
ェリン類とが結合した状態のものであって、結合のしか
たとしては、鉄とラクトフェリン類とが直接結合してい
ても、あるいは、他の物質を介して結合した状態のもの
であってもよく、いわゆる、鉄がイオンの状態で存在し
ていないものであればよい。特に、ラクトフェリン類に
炭酸及び／又は重炭酸と鉄とが結合した、鉄−ラクトフ
ェリン結合体〔特開平6-239900号公報〕や鉄−ラクトフ
ェリン複合体〔特開平7-304798号公報〕を用いることが
好ましい。これらの鉄−ラクトフェリン結合体及び鉄−
ラクトフェリン複合体は、ラクトフェリン類1g当たり、
15mg以上の炭酸及び／又は重炭酸と10〜700mg の鉄が結
合した鉄−ラクトフェリンであり、耐熱性を有するので
加熱しても沈殿が生じないし、鉄の収斂味や金属味も呈
さないという優れた適性を有しており、飲食品に添加し
て用いる場合には特に有利なものである。In the present invention, as iron-lactoferrin,
Any of the above can be used. That is, the iron-lactoferrin referred to in the present invention is a state in which iron and lactoferrin are bonded, and the bonding method is such that iron and lactoferrin are directly bonded or other substances. May be used as long as the iron is not present in an ionic state. In particular, use of an iron-lactoferrin conjugate (JP-A-6-239900) or an iron-lactoferrin complex (JP-A-7-304798), in which carbonic acid and / or bicarbonate and iron are bonded to lactoferrins. Is preferred. These iron-lactoferrin conjugates and iron-
Lactoferrin complex, per 1 g of lactoferrins,
An iron-lactoferrin in which 15 mg or more of carbonic acid and / or bicarbonate is combined with 10 to 700 mg of iron. Since it has heat resistance, it does not precipitate even when heated and does not exhibit the astringent taste or metallic taste of iron. It is particularly advantageous when used in foods and drinks.
【００１０】鉄−ラクトフェリンを製造する際に原料と
して使用できるラクトフェリン類としては、哺乳類の乳
等の分泌液から分離されるラクトフェリンを例示するこ
とができるが、血液や臓器等から分離されるトランスフ
ェリンや卵等から分離されるオボトランスフェリン等も
同様の特性を有しており、ラクトフェリン類と同様に使
用することが可能である。また、ラクトフェリン類は、
完全に単離されている必要はなく、他の成分が含まれて
いる状態のものであっても構わない。さらに、微生物、
動物細胞、トランスジェニック動物等から遺伝子操作に
より産生されたラクトフェリン類も使用することが可能
である。本発明においては、上記したラクトフェリン、
トランスフェリンを含めてラクトフェリン類と称する。
そして、ラクトフェリン類をトリプシン、ペプシン、キ
モトリプシン等の酵素で加水分解したものも使用するこ
ともできる。Examples of lactoferrins that can be used as a raw material in producing iron-lactoferrin include lactoferrin isolated from secretions of milk and the like of mammals, and transferrin and lactoferrin isolated from blood and organs can be exemplified. Ovotransferrin isolated from eggs and the like also has similar properties, and can be used in the same manner as lactoferrins. In addition, lactoferrins,
It does not need to be completely isolated, and may be a state containing other components. In addition, microorganisms,
Lactoferrin produced by genetic manipulation from animal cells, transgenic animals and the like can also be used. In the present invention, the lactoferrin described above,
It is referred to as lactoferrins including transferrin.
Lactoferrin hydrolyzed with enzymes such as trypsin, pepsin, and chymotrypsin can also be used.
【００１１】また、本発明で用いる鉄−ラクトフェリン
を製造する際に原料として使用できる鉄としては、硫酸
第一鉄、グルコン酸第一鉄、乳酸鉄、クエン酸鉄、クエ
ン酸第一鉄ナトリウム、クエン酸鉄アンモニウム、ピロ
リン酸第一鉄、ピロリン酸第二鉄、塩化第二鉄、硝酸第
二鉄、硫酸第二鉄等を例示することができる。The iron which can be used as a raw material in producing the iron-lactoferrin used in the present invention includes ferrous sulfate, ferrous gluconate, iron lactate, iron citrate, sodium ferrous citrate, Examples include iron ammonium citrate, ferrous pyrophosphate, ferric pyrophosphate, ferric chloride, ferric nitrate, and ferric sulfate.
【００１２】本発明の骨強化剤は、鉄−ラクトフェリン
を有効成分とするものであるが、他の栄養成分、例えば
カルシウム、マグネシウム、ビタミンＤ、ビタミンＫ、
各種オリゴ糖等、骨代謝に寄与する成分を併せて配合し
ても構わない。The bone strengthening agent of the present invention contains iron-lactoferrin as an active ingredient. Other nutrients such as calcium, magnesium, vitamin D, vitamin K,
Components that contribute to bone metabolism, such as various oligosaccharides, may be added together.
【００１３】本発明の骨強化剤は、製剤の分野において
通常使用されている製剤成分、例えば、増量剤、希釈
剤、溶剤や充填剤等のような賦形剤、溶解補助剤、可溶
化剤、乳化剤、懸濁化剤、分散剤、結合剤、滑沢剤、コ
ーティング剤や徐放化剤等のような補助剤、あるいは、
抗酸化剤、保存剤、光沢剤、甘味剤、着色剤、着香剤等
の添加物と混合し、常法にしたがって、錠剤、カプセル
剤、顆粒剤、丸剤、ドリンク剤、シロップ剤、液剤等の
種々の剤形の製剤とすることができる。The bone-enhancing agent of the present invention can be prepared by using ingredients usually used in the field of pharmaceuticals, for example, fillers, diluents, excipients such as solvents and fillers, solubilizing agents, solubilizing agents. , Emulsifiers, suspending agents, dispersants, binders, lubricants, auxiliary agents such as coating agents and sustained release agents, or
Mix with additives such as antioxidants, preservatives, brighteners, sweeteners, coloring agents, flavoring agents, etc., and in the usual manner tablets, capsules, granules, pills, drinks, syrups, liquids And the like.
【００１４】また、本発明の骨強化剤は、チーズ、バタ
ー、発酵乳等の乳食品、飲料乳、ドリンクヨーグルト、
コーヒー飲料、果汁等の飲料、ゼリー、プリン、クッキ
ー、ビスケット、ウエハース等の菓子、さらには、冷凍
食品等の各種の形態の飲食品に添加して、骨強化作用を
賦与した飲食品とすることができる。Further, the bone strengthening agent of the present invention includes milk foods such as cheese, butter, and fermented milk, beverage milk, drink yogurt,
Add to beverages such as coffee drinks, fruit juices, confectionery such as jelly, pudding, cookies, biscuits, wafers, and various types of foods and beverages such as frozen foods, to provide foods and beverages with bone strengthening action Can be.
【００１５】これらの製剤や飲食品に配合することがで
きる鉄−ラクトフェリンの量については特に制限はない
が、剤形や飲食品の形態に応じて、成人一人一日当たり
鉄を１〜10mg摂取できるように鉄−ラクトフェリンを配
合することが好ましい。There is no particular limitation on the amount of iron-lactoferrin that can be incorporated in these preparations and foods and drinks, but depending on the dosage form and the form of food and drink, one adult can take in 1 to 10 mg of iron per day. It is preferable to mix iron-lactoferrin as described above.
【００１６】以下、参考例、実施例及び試験例を示し、
本発明を具体的に説明する。Hereinafter, reference examples, examples and test examples will be shown.
The present invention will be specifically described.
【００１７】[0017]
【参考例１】ウシラクトフェリン 90gと塩化第二鉄６水
和物 52gを水10リットルに溶解し、攪拌機で攪拌しなが
ら重炭酸ナトリウム5gを添加して鉄−ラクトフェリンを
含む溶液を調製した。そして、この溶液を分子量 5,000
カットの限外濾過膜で脱塩及び濃縮した後、水を加えて
容量10リットルの鉄−ラクトフェリン溶液とした。な
お、この鉄−ラクトフェリン溶液中の鉄量を誘導結合プ
ラズマ発光分光器(ICP)(ST-3000、Leeman Labs 社製)
で測定したところ、鉄−ラクトフェリン溶液中に含まれ
る鉄量は 102mg/100mlであった。この鉄−ラクトフェリ
ンは、誘導結合プラズマ発光分光器(ICP) 分析及び元素
分析を行ったところ、ラクトフェリン１分子当たりに鉄
を 105原子、重炭酸を５分子含んでいた。Reference Example 1 90 g of bovine lactoferrin and 52 g of ferric chloride hexahydrate were dissolved in 10 liters of water, and 5 g of sodium bicarbonate was added while stirring with a stirrer to prepare a solution containing iron-lactoferrin. Then, this solution is used for
After desalting and concentration using a cut ultrafiltration membrane, water was added to obtain a 10-liter iron-lactoferrin solution. The amount of iron in the iron-lactoferrin solution was determined by an inductively coupled plasma emission spectrometer (ICP) (ST-3000, manufactured by Leeman Labs).
As a result, the amount of iron contained in the iron-lactoferrin solution was 102 mg / 100 ml. This iron-lactoferrin was subjected to inductively coupled plasma emission spectroscopy (ICP) analysis and elemental analysis and found to contain 105 atoms of iron and 5 molecules of bicarbonate per lactoferrin molecule.
【００１８】[0018]
【参考例２】水２リットルに重炭酸ナトリウム400gを添
加し、攪拌機で攪拌して調製した重炭酸ナトリウム過飽
和溶液中に、水８リットルにウシラクトフェリン 90gと
塩化第二鉄６水和物 52gを溶解した溶液を攪拌しながら
添加し、鉄−ラクトフェリンを含む溶液を調製した。こ
の溶液を分子量 5,000カットの限外濾過膜で脱塩及び濃
縮した後、水を加えて容量10リットルの鉄−ラクトフェ
リン溶液とした。なお、この鉄−ラクトフェリン溶液中
の鉄量を誘導結合プラズマ発光分光器(ICP) で測定した
ところ、鉄−ラクトフェリン溶液中に含まれる鉄量は 1
01mg/100mlであった。この鉄−ラクトフェリンは、ラク
トフェリン１分子当たりに鉄を 108原子、重炭酸を54分
子含んでいた。REFERENCE EXAMPLE 2 400 g of sodium bicarbonate was added to 2 liters of water, and 90 g of bovine lactoferrin and 52 g of ferric chloride hexahydrate were added to 8 liters of water in a supersaturated sodium bicarbonate solution prepared by stirring with a stirrer. The dissolved solution was added with stirring to prepare a solution containing iron-lactoferrin. The solution was desalted and concentrated using an ultrafiltration membrane having a molecular weight of 5,000, and water was added to obtain a 10-liter iron-lactoferrin solution. When the amount of iron in the iron-lactoferrin solution was measured by an inductively coupled plasma emission spectrometer (ICP), the amount of iron contained in the iron-lactoferrin solution was 1%.
It was 01 mg / 100 ml. This iron-lactoferrin contained 108 atoms of iron and 54 molecules of bicarbonate per lactoferrin molecule.
【００１９】[0019]
【試験例１】３週齢のWistar系雌ラット32匹に鉄欠乏飼
料を14日間摂取させ、貧血ラットを作製して実験に用い
た。実験群は１群８匹の４群とし、各群に下記の鉄溶液
を１日当たり50μｇの鉄量となるように、経口ゾンデに
て１日１回、４週間連日投与した。なお、投与期間中も
ラットには鉄欠乏飼料を摂取させた。投与終了後、大腿
骨を摘出し、骨密度測定装置（DCS-600A、アロカ社製）
にて大腿骨の骨密度を測定した。さらに、骨破断強度測
定装置（レオメーターマックス、アイテクノ社製）にて
大腿骨の破断強度を測定した。実験群を以下に示す。Test Example 1 Thirty-two 3-week-old Wistar female rats were fed an iron-deficient diet for 14 days, and anemic rats were prepared and used in the experiment. The experimental group consisted of 4 groups of 8 animals, and the following iron solution was administered to each group once a day using an oral sonde once daily for 4 weeks so that the iron amount was 50 μg per day. The rats were also fed an iron-deficient diet during the administration period. After the administration, the femur is removed and a bone density measuring device (DCS-600A, manufactured by Aloka)
And the bone density of the femur was measured. Further, the fracture strength of the femur was measured by a bone fracture strength measuring device (Rheometer Max, manufactured by Eye Techno Co., Ltd.). The experimental groups are shown below.
【００２０】Ａ群：参考例１で調製した鉄−ラクトフェ
リン溶液を、20mg/100mlの鉄量となるように希釈した溶
液を投与 Ｂ群：参考例２で調製した鉄−ラクトフェリン溶液を、
20mg/100mlの鉄量となるように希釈した溶液を投与 Ｃ群：クエン酸第一鉄ナトリウムを、20mg/100mlの鉄量
となるように溶解した溶液を投与 Ｄ群：硫酸第一鉄７水和物を、20mg/100mlの鉄量となる
ように溶解した溶液を投与 結果を表１に示す。Group A: A solution prepared by diluting the iron-lactoferrin solution prepared in Reference Example 1 so as to have an iron amount of 20 mg / 100 ml was administered. Group B: The iron-lactoferrin solution prepared in Reference Example 2 was administered.
A solution diluted to an iron amount of 20 mg / 100 ml was administered. Group C: A solution in which sodium ferrous citrate was dissolved to an iron amount of 20 mg / 100 ml was administered. Group D: Ferrous sulfate 7 water Table 1 shows the results of administration of a solution prepared by dissolving the Japanese iron so as to have an iron content of 20 mg / 100 ml.
【００２１】[0021]
【表１】 [Table 1]
【００２２】大腿骨の骨密度及び破断強度ともに、鉄−
ラクトフェリンを投与したＡ群及びＢ群で明らかに高い
値を示しており、鉄−ラクトフェリンが骨強化作用を有
することが明らかとなった。Both the bone density and breaking strength of the femur are iron-
The lactoferrin-administered groups A and B showed clearly higher values, indicating that iron-lactoferrin has a bone strengthening effect.
【００２３】[0023]
【実施例１】参考例１で調製した鉄−ラクトフェリン溶
液を凍結乾燥して得られた鉄−ラクトフェリン粉末とカ
ルシウムとを含有するタブレットを製造した。すなわ
ち、炭酸カルシウム20％、鉄−ラクトフェリン粉末10
％、マルトース40％、エリスリトール16％、ソルビトー
ル２％、香料４％、甘味料 0.5％、賦形剤５％、滑択剤
2.5％の組成で原料を混合し、常法により打錠し、骨強
化剤タブレットを製造した。なお、このタブレットには
１錠(500mg) 当たり鉄が 3.7mg含まれていた。Example 1 A tablet containing calcium and an iron-lactoferrin powder obtained by freeze-drying the iron-lactoferrin solution prepared in Reference Example 1 was produced. That is, calcium carbonate 20%, iron-lactoferrin powder 10
%, Maltose 40%, erythritol 16%, sorbitol 2%, flavor 4%, sweetener 0.5%, excipient 5%, lubricant
The raw materials were mixed at a composition of 2.5% and tableted by a conventional method to produce a bone strengthening tablet. This tablet contained 3.7 mg of iron per tablet (500 mg).
【００２４】[0024]
【実施例２】参考例２で調製した鉄−ラクトフェリンを
含有する清涼飲料水を調製した。すなわち、組成が鉄−
ラクトフェリン溶液５％、50％乳酸溶液0.12％、マルチ
トール 7.5％、香料 0.2％、水 87.18％である原料を混
合し、プレート殺菌機を用いて90℃、15秒間殺菌し、骨
強化作用を賦与した清涼飲料水を製造した。なお、この
清涼飲料水には 100ml当たり鉄が５mg含まれていた。Example 2 Soft drink containing iron-lactoferrin prepared in Reference Example 2 was prepared. That is, the composition is iron-
A mixture of 5% lactoferrin solution, 50% lactic acid solution 0.12%, maltitol 7.5%, fragrance 0.2%, water 87.18% is mixed and sterilized using a plate sterilizer at 90 ° C for 15 seconds to give bone strengthening action. A soft drink was prepared. The soft drink contained 5 mg of iron per 100 ml.
【００２５】[0025]
【実施例３】参考例２で調製した鉄−ラクトフェリン溶
液を凍結乾燥して得られた鉄−ラクトフェリンを、鉄含
量が3mg/100gとなるように生乳に添加し、150kgf/cm2で
均質処理を行い、プレート殺菌機を用いて 130℃、２秒
間殺菌し、骨強化作用を賦与した乳飲料を製造した。Example 3 Iron-lactoferrin obtained by freeze-drying the iron-lactoferrin solution prepared in Reference Example 2 was added to raw milk so that the iron content became 3 mg / 100 g, and homogenized at 150 kgf / cm 2. The mixture was sterilized using a plate sterilizer at 130 ° C. for 2 seconds to produce a milk beverage having a bone strengthening effect.
【００２６】[0026]
【発明の効果】以上説明した通り、本発明の鉄−ラクト
フェリンを有効成分とする骨強化剤は、骨粗鬆症等の各
種骨疾患の予防及び治療に有効である。As described above, the bone enhancer containing iron-lactoferrin of the present invention as an active ingredient is effective for the prevention and treatment of various bone diseases such as osteoporosis.
【００２７】また、本発明の骨強化剤は、チーズ、バタ
ー、発酵乳等の乳食品、飲料乳、ドリンクヨーグルト、
コーヒー飲料、果汁等の飲料、ゼリー、プリン、クッキ
ー、ビスケット、ウエハース等の菓子、冷凍食品等の各
種の形態の飲食品に添加し、骨強化作用を賦与した飲食
品とすることができ、有用である。[0027] The bone enhancer of the present invention may be used for milk foods such as cheese, butter, and fermented milk, beverage milk, drink yogurt,
It can be added to various forms of foods and drinks such as coffee drinks, fruit juices and other drinks, jelly, pudding, cookies, biscuits, wafers and other confections, frozen foods, etc. It is.
───────────────────────────────────────────────────── フロントページの続き Ｆターム(参考） 4C084 AA02 BA33 BA44 DC50 MA17 MA23 MA35 MA37 MA41 MA52 NA14 ZA552 ZA961 ZA962 ZA971 ZA972 ──────────────────────────────────────────────────続 き Continued on the front page F term (reference) 4C084 AA02 BA33 BA44 DC50 MA17 MA23 MA35 MA37 MA41 MA52 NA14 ZA552 ZA961 ZA962 ZA971 ZA972
Claims (4)
も３原子の鉄を保持している鉄−ラクトフェリンを有効
成分とする骨強化剤。1. A bone-enhancing agent comprising iron-lactoferrin as an active ingredient and having at least 3 atoms of iron per lactoferrin molecule.
類に炭酸及び／又は重炭酸と鉄とが結合している鉄−ラ
クトフェリン結合体及び／又は鉄−ラクトフェリン複合
体である請求項１記載の骨強化剤。2. The bone strengthening agent according to claim 1, wherein the iron-lactoferrin is an iron-lactoferrin conjugate and / or an iron-lactoferrin complex in which carbonic acid and / or bicarbonate and iron are bonded to lactoferrins. .
類1g当たり、15mg以上の炭酸及び／又は重炭酸と10〜70
0mg の鉄とが結合している鉄−ラクトフェリン結合体及
び／又は鉄−ラクトフェリン複合体である請求項１記載
の骨強化剤。3. An iron-lactoferrin is used in an amount of 10 to 70 mg or more of carbonic acid and / or bicarbonate per 1 g of lactoferrin.
The bone enhancer according to claim 1, which is an iron-lactoferrin conjugate and / or an iron-lactoferrin complex bound to 0 mg of iron.
類1g当たり、35〜400mg の炭酸及び／又は重炭酸と40〜
500mg の鉄とが結合している鉄−ラクトフェリン結合体
及び／又は鉄−ラクトフェリン複合体である請求項１記
載の骨強化剤。4. An iron-lactoferrin comprising 35 to 400 mg of carbonic acid and / or bicarbonate per 40 g of lactoferrins.
The bone enhancer according to claim 1, which is an iron-lactoferrin conjugate and / or an iron-lactoferrin complex bound to 500 mg of iron.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09056199A JP3739589B2 (en) | 1999-03-31 | 1999-03-31 | Bone strengthening agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09056199A JP3739589B2 (en) | 1999-03-31 | 1999-03-31 | Bone strengthening agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000281586A true JP2000281586A (en) | 2000-10-10 |
| JP3739589B2 JP3739589B2 (en) | 2006-01-25 |
Family
ID=14001845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09056199A Expired - Fee Related JP3739589B2 (en) | 1999-03-31 | 1999-03-31 | Bone strengthening agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3739589B2 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003082921A1 (en) | 2002-04-03 | 2003-10-09 | Fonterra Research Centre Limited | Lactoferrin |
| US6806069B2 (en) * | 2001-01-09 | 2004-10-19 | Pharmachem Laboratories, Inc. | Ubiquinone composition and methods related thereto |
| JP2005119983A (en) * | 2003-10-14 | 2005-05-12 | Snow Brand Milk Prod Co Ltd | Nutritive composition |
| JP2007197327A (en) * | 2006-01-23 | 2007-08-09 | Snow Brand Milk Prod Co Ltd | Lipid metabolism improving agent |
| EP1576964A4 (en) * | 2002-11-29 | 2008-06-11 | Morinaga Milk Industry Co Ltd | Protease inhibitor |
| EP2156820A1 (en) * | 2007-05-25 | 2010-02-24 | Snow Brand Milk Products, Co., Ltd. | Skin whitening agent |
| JP2016523870A (en) * | 2013-07-05 | 2016-08-12 | ネステク ソシエテ アノニム | Lactoferrin-osteopontin-iron complex |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075411A (en) * | 2016-07-12 | 2016-11-09 | 方雅悯 | A kind of preparation method of natural iron supplement soft capsule |
-
1999
- 1999-03-31 JP JP09056199A patent/JP3739589B2/en not_active Expired - Fee Related
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6806069B2 (en) * | 2001-01-09 | 2004-10-19 | Pharmachem Laboratories, Inc. | Ubiquinone composition and methods related thereto |
| US20110183008A1 (en) * | 2002-04-03 | 2011-07-28 | Jillian Cornish | Lactoferrin |
| EP1490404A4 (en) * | 2002-04-03 | 2010-02-24 | Fonterra Researcg Ct Ltd | Lactoferrin |
| WO2003082921A1 (en) | 2002-04-03 | 2003-10-09 | Fonterra Research Centre Limited | Lactoferrin |
| CN1625566B (en) * | 2002-04-03 | 2012-10-10 | 方塔拉研究中心有限公司 | Lactoferrin |
| US8703699B2 (en) * | 2002-04-03 | 2014-04-22 | Auckland Uniservices Limited | Lactoferrin |
| EP1576964A4 (en) * | 2002-11-29 | 2008-06-11 | Morinaga Milk Industry Co Ltd | Protease inhibitor |
| JP2005119983A (en) * | 2003-10-14 | 2005-05-12 | Snow Brand Milk Prod Co Ltd | Nutritive composition |
| JP4596513B2 (en) * | 2003-10-14 | 2010-12-08 | 雪印乳業株式会社 | Nutritional composition |
| JP2007197327A (en) * | 2006-01-23 | 2007-08-09 | Snow Brand Milk Prod Co Ltd | Lipid metabolism improving agent |
| EP2156820A1 (en) * | 2007-05-25 | 2010-02-24 | Snow Brand Milk Products, Co., Ltd. | Skin whitening agent |
| EP2156820A4 (en) * | 2007-05-25 | 2010-11-24 | Snow Brand Milk Products Co Ltd | Skin whitening agent |
| AU2008255930B2 (en) * | 2007-05-25 | 2014-02-27 | Megmilk Snow Brand Co., Ltd. | Skin whitening agent |
| JP2016523870A (en) * | 2013-07-05 | 2016-08-12 | ネステク ソシエテ アノニム | Lactoferrin-osteopontin-iron complex |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3739589B2 (en) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4592127B2 (en) | Bone resorption inhibitor | |
| JP4970694B2 (en) | Persistent muscle fatigue improver | |
| TW433987B (en) | Calcium complex and food fortified therewith | |
| JP4536341B2 (en) | Bone formation promoter | |
| CA2281054C (en) | Combination of zinc ions and vitamin c and method of making | |
| JP2001346519A (en) | Method for producing fraction containing high content of milk basic cystatin and decomposed product thereof | |
| JP3739589B2 (en) | Bone strengthening agent | |
| JP2002523025A (en) | Composition | |
| JP2003503038A (en) | Preventive supplements based on milk | |
| JP3459932B2 (en) | Anti-osteoporosis composition | |
| JP5414142B2 (en) | Lipid metabolism improver | |
| JP4647750B2 (en) | Fraction containing high amount of milk basic cystatin and method for producing degradation product thereof | |
| JPH0621077B2 (en) | Hematopoietic agent | |
| JP2975337B2 (en) | Calcium complex | |
| JPH10257867A (en) | Food for improving hypoalbuminaemia | |
| JP2735375B2 (en) | Iron agent, its manufacturing method and iron-fortified food manufacturing method | |
| JPH11310599A (en) | Polymer type calcium/phosphopeptide complex | |
| JPH0797323A (en) | Iron absorption promoter | |
| TW200800292A (en) | Accelerating agent of calcium absorption | |
| JP5100923B2 (en) | Calcium-phosphorylated starch complex and method for producing the same | |
| JPH10117728A (en) | Calcium absorption promoter | |
| JPH10262570A (en) | Iron-caseinphosphopeptide complex and production thereof | |
| JP2964290B2 (en) | Mineral absorption enhancer | |
| JP3560309B2 (en) | Calcium absorption promoting nutritional composition | |
| JPH07308172A (en) | Casein phosphopeptide-containing food or drink for person having low calcium absorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040727 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040927 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040928 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050801 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050929 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051027 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051102 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091111 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091111 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091111 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091111 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091111 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101111 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111111 Year of fee payment: 6 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111111 Year of fee payment: 6 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111111 Year of fee payment: 6 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111111 Year of fee payment: 6 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111111 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121111 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121111 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131111 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |